REVVITY, INC.

Previous wording

Overview of the Second Quarter of Fiscal Year 2026

Current wording

Overview of the Third Quarter of Fiscal Year 2026

Previous wording

Our overall revenue in the second quarter of fiscal year 2026 was $729.7 million which increased by $9.4 million, or 1%, as compared to the second quarter of fiscal year 2025, reflecting an increase of $16.6 million, or 5%, in our Diagnostics segment revenue, and a decrease of $7.2 million, or 2%, in our Life Sciences segment revenue. The increase in our Diagnostics segment revenue for the second quarter of fiscal year 2026 was driven by both our Reproductive Health business and favorable changes in foreign exchange rates. The decrease in our Life Sciences segment revenue for the second quarter of fiscal year 2026 was driven by a decline in revenue in our Software business.

Current wording

Our overall revenue in the third quarter of fiscal year 2026 was $728.9 million which increased by $30.0 million, or 4%, as compared to the third quarter of fiscal year 2025, reflecting an increase of $36.8 million, or 11%, in our Life Sciences segment revenue, and a decrease of $6.8 million, or 2%, in our Diagnostics segment revenue. The increase in our Life Sciences segment revenue for the third quarter of fiscal year 2026 was driven by an increase in both Life Sciences Solutions and Software business. The decrease in our Diagnostics segment revenue for the third quarter of fiscal year 2026 was driven by a decrease in our Immunodiagnostics business partially offset by an increase in our Reproductive Health business.

Previous wording

Our consolidated gross margins increased 260 basis points from 54.5% to 57.1% in the second quarter of fiscal year 2026, as compared to the second quarter of fiscal year 2025, primarily due to tariff refunds and product mix shift. Our consolidated operating margins decreased from 12.6% to 12.2% in the second quarter of fiscal year 2026, as compared to the second quarter of fiscal year 2025, primarily due to restructuring charges and digital investments.

Current wording

Our consolidated gross margins increased 380 basis points from 53.6% to 57.4% in the third quarter of fiscal year 2026, as compared to the third quarter of fiscal year 2025, primarily due to favorable product mix shift and restructuring benefit. Our consolidated operating margins increased 130 basis points from 11.7% to 13.1% in the third quarter of fiscal year 2026, as compared to the third quarter of fiscal year 2025, primarily due to improvements in gross margins and cost productivity partially offset by restructuring charges.

Previous wording

For a more detailed discussion of our critical accounting policies and estimates, refer to the Notes to our audited consolidated financial statements and Item 7.“Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in our Annual Report on Form 10-K for the fiscal year ended December 28, 2025 (our “2025 Form 10-K”), as filed with the Securities and Exchange Commission. There have been no significant changes in our critical accounting policies and estimates during the six months ended July 5, 2026.

Current wording

For a more detailed discussion of our critical accounting policies and estimates, refer to the Notes to our audited consolidated financial statements and Item 7.“Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in our Annual Report on Form 10-K for the fiscal year ended December 28, 2025 (our “2025 Form 10-K”), as filed with the Securities and Exchange Commission. There have been no significant changes in our critical accounting policies and estimates during the nine months ended October 4, 2026.

Previous wording

Revenue for the three months ended July 5, 2026 was $729.7 million, as compared to $720.3 million for the three months ended June 29, 2025, an increase of $9.4 million, or 1%. The analysis in the remainder of this paragraph comp ares segment revenue and includes the effect of foreign exchange rate fluctuations. Life Sciences segment revenue was $358.7 million for the three months ended July 5, 2026, as compared to $365.9 million for the three months ended June 29, 2025, a decrease of $7.2 million, or 2%, driven by a decrease of $10.2 million in Software revenue, partially offset by an increase of $3.0 million in Life Sciences Solutions revenue. Diagnostics segment revenue was $371.0 million for the three months ended July 5, 2026, as compared to $354.4 million for the three months ended June 29, 2025, an increase of $16.6 million, or 5%, due to an increase of $20.7 million in Reproductive Health revenue, partially offset by a decrease of $4.1 million in Immunodiagnostics revenue.

Current wording

Revenue for the three months ended October 4, 2026 was $728.9 million, as compared to $698.9 million for the three months ended September 28, 2025, an increase of $30.0 million, or 4%. The analysis in the remainder of this paragraph comp ares segment revenue and includes the effect of foreign exchange rate fluctuations. Life Sciences segment revenue was $379.6 million for the three months ended October 4, 2026, as compared to $342.8 million for the three months ended September 28, 2025, an increase of $36.8 million, or 11%, driven by an increase of $21.6 million in Life Sciences Solutions revenue and an increase of $15.2 million in Software revenue. Diagnostics segment revenue was $349.3 million for the three months ended October 4, 2026, as compared to $356.1 million for the three months ended September 28, 2025, a decrease of $6.8 million, or 2%, due to a decrease of $10.5 million in Immunodiagnostics revenue, partially offset by an increase of $3.7 million in Reproductive Health revenue.

Previous wording

Revenue for the six months ended July 5, 2026 was $1,440.8 million, as compared to $1,385.0 million for the six months ended June 29, 2025, an increase of $55.8 million, or 4%. The analysis in the remainder of this paragraph comp ares segment revenue and includes the effect of foreign exchange rate fluctuations. Life Sciences segment revenue was $720.5 million for the six months ended July 5, 2026, as compared to $706.3 million for the six months ended June 29, 2025, an increase of $14.3 million, or 2%, driven by an increase of $16.5 million in Life Sciences Solutions revenue, partially offset by a decrease of $2.3 million in Software revenue. Diagnostics segment revenue was $720.3 million for the six months ended July 5, 2026, as compared to $678.8 million for the six months ended June 29, 2025, an increase of $41.5 million, or 6%, due to an increase of $41.3 million in Reproductive Health revenue and an increase of $0.2 million in Immunodiagnostics revenue. Both the Life Sciences and the Diagnostics segments benefited from an extra fiscal week forthe six months ended July 5, 2026.

Current wording

Revenue for the nine months ended October 4, 2026 was $2,169.7 million, as compared to $2,084.0 million for the nine months ended September 28, 2025, an increase of $85.7 million, or 4%. The analysis in the remainder of this paragraph comp ares segment revenue and includes the effect of foreign exchange rate fluctuations. Life Sciences segment revenue was $1,100.1 million for the nine months ended October 4, 2026, as compared to $1,049.1 million for the nine months ended September 28, 2025, an increase of $51.0 million, or 5%, driven by an increase of $38.1 million in Life Sciences Solutions revenue and an increase of $12.9 million in Software revenue. Diagnostics segment revenue was $1,069.6 million for the nine months ended October 4, 2026, as compared to $1,034.9 million for the nine months ended September 28, 2025, an increase of $34.7 million, or 3%, due to an increase of $45.0 million in Reproductive Health revenue, partially offset by a decrease of $10.3 million in Immunodiagnostics revenue. Both the Life Sciences and the Diagnostics segments benefited from an extra fiscal week for the nine months ended October 4, 2026.

Previous wording

Cost of revenue for the three months ended July 5, 2026 was $312.8 million, as compared to $327.7 million for the three months ended June 29, 2025, a decrease of $14.9 million, or 5%. As a percentage of revenue, cost of revenue decreased to 42.9% for the three months ended July 5, 2026, from 45.5% for the three months ended June 29, 2025, resulting in an increase in gross margin of 260 basis points to 57.1% for the three months ended July 5, 2026, from 54.5% for the three months ended June 29, 2025, primarily due to tariff refunds and product mix shift. Amortization of intangible assets was $34.8 million for the three months ended July 5, 2026, as compared to $36.5 million for the three months ended June 29, 2025.

Current wording

Cost of revenue for the three months ended October 4, 2026 was $310.3 million, as compared to $324.3 million for the three months ended September 28, 2025, a decrease of $14.0 million, or 4%. The analysis in the remainder of this paragraph includes the effect of foreign exchange rate fluctuations. As a percentage of revenue, cost of revenue decreased to 42.6% for the three months ended October 4, 2026, from 46.4% for the three months ended September 28, 2025, resulting in an increase in gross margin of 380 basis points to 57.4% for the three months ended October 4, 2026, from 53.6% for the three months ended September 28, 2025, primarily due to favorable product mix shift and restructuring benefit. Amortization of intangible assets was $34.6 million for the three months ended October 4, 2026, as compared to $35.3 million for the three months ended September 28, 2025.

Previous wording

Cost of revenue for the six months ended July 5, 2026 was $636.3 million, as compared to $616.9 million for the six months ended June 29, 2025, an increase of $19.3 million, or 3%. As a percentage of revenue, cost of revenue decreased to 44.2% for the six months ended July 5, 2026, from 44.5% for the six months ended June 29, 2025, resulting in an increase in gross margin of 40 basis points to 55.8% for the six months ended July 5, 2026, from 55.5% for the six months ended June 29, 2025, primarily due to tariff refunds and product mix shift. Amortization of intangible assets was $69.8 million for the six months ended July 5, 2026, as compared to $70.9 million for the six months ended June 29, 2025.

Current wording

Cost of revenue for the nine months ended October 4, 2026 was $946.6 million, as compared to $941.3 million for the nine months ended September 28, 2025, an increase of $5.3 million, or 1%. The analysis in the remainder of this paragraph includes the effect of foreign exchange rate fluctuations. As a percentage of revenue, cost of revenue decreased to 43.6% for the nine months ended October 4, 2026, from 45.2% for the nine months ended September 28, 2025, resulting in an increase in gross margin of 150 basis points to 56.4% for the nine months ended October 4, 2026, from 54.8% for the nine months ended September 28, 2025, primarily due to tariffs refunds, favorable product mix shift, and restructuring benefit. Amortization of intangible assets was $104.3 million for the nine months ended October 4, 2026, as compared to $106.2 million for the nine months ended September 28, 2025.

Previous wording

On February 20, 2026, the United States Supreme Court ruled that the International Emergency Economic Powers Act does not authorize the imposition of tariffs. In April 2026, the U.S. Customs and Border Protection (CBP) announced a new administrative process for importers to utilize in seeking to obtain refunds. Through the established CBP refund process, the Company applied for $20.2 million of refunds and received $16.2 million through July 5, 2026. The timing and amount of additional recoveries remain uncertain and will depend on the scope and timing of court or administrative developments and completion of applicable administrative steps. Accordingly, refunds have been recorded in income upon receipt of payment, and no refund receivable has been recorded as of July 5, 2026. As a result, $16.2 million of refunds were recorded in cost of revenue for the three months ended July 5, 2026.

Current wording

On February 20, 2026, the United States Supreme Court ruled that the International Emergency Economic Powers Act does not authorize the imposition of tariffs. In April 2026, the U.S. Customs and Border Protection (CBP) announced a new administrative process for importers to utilize in seeking to obtain refunds. Through the established CBP refund process, the Company applied for $20.2 million of refunds. Refunds have been recorded in income upon receipt of payment, and no refund receivable has been recorded as of October 4, 2026.

Previous wording

Selling, general and administrative expenses for the three months ended July 5, 2026 were $278.6 million, as compared to $248.5 million for the three months ended June 29, 2025, an increase of $30.1 million, or 12%. As a percentage of revenue, selling, general and administrative expenses increased and were 38.2% for the three months ended July 5, 2026, as compared to 34.5% for the three months ended June 29, 2025. Amortization of intangible assets increased and was $50.1 million for the three months ended July 5, 2026, as compared to $48.8 million for the three months ended June 29, 2025. Restructuring and other costs increased and were $35.5 million for the three months ended July 5, 2026, as compared to $11.2 million for the three months ended June 29, 2025. Restructuring and other costs in the second quarter of fiscal year 2026 primarily consisted of charges associated with workforce reductions and facility consolidations in an effort to streamline operations, other exit costs, abandonments or associated asset write-downs, costs of terminating certain lease agreements or contracts, as well as costs associated with relocating facilities. In the second quarter of fiscal year 2026, severance actions associated with facility consolidations and cost reduction measures affected approximately 3% of our workforce. The above increases were partially offset by a decrease in purchase accounting adjustments, which were $1.7 million for the three months ended July 5, 2026, and primarily consisted of a change in contingent consideration, as compared to $2.0 million for the three months ended June 29, 2025. Acquisition and divestiture-related expenses, which primarily consisted of legal and integration costs, were $0.1 million for the three months ended July 5, 2026, as compared to $1.2 million for the three months ended June 29, 2025. Significant litigation matters and settlements decreased, and were $0.1 million for the three months ended July 5, 2026, as compared to $1.1 million for the three months ended June 29, 2025. Transformation costs were a net credit of $0.7 million for the three months ended July 5, 2026. Excluding the items noted above, selling, general and administrative expenses increased due to digital investments and employee incentive compensation.

Current wording

Selling, general and administrative expenses for the three months ended October 4, 2026 were $275.3 million, as compared to $241.9 million for the three months ended September 28, 2025, an increase of $33.4 million, or 14%. The analysis in the remainder of this paragraph includes the effect of foreign exchange rate fluctuations. As a percentage of revenue, selling, general and administrative expenses increased and were 37.8% for the three months ended October 4, 2026, as compared to 34.6% for the three months ended September 28, 2025. Amortization of intangible assets increased and was $50.1 million for the three months ended October 4, 2026, as compared to $48.7 million for the three months ended September 28, 2025. Restructuring and other costs increased and were $28.4 million for the three months ended October 4, 2026, as compared to $9.9 million for the three months ended September 28, 2025. Restructuring and other costs in the third quarter of fiscal year 2026 primarily consisted of charges associated with workforce reductions and facility consolidations in an effort to streamline operations, other exit costs, abandonments or associated asset write-downs, costs of terminating certain lease agreements or contracts, as well as costs associated with relocating facilities. In the third quarter of fiscal year 2026, severance actions associated with facility consolidations and cost reduction measures affected approximately 2% of our workforce. The above increases were partially offset by a decrease in purchase accounting adjustments, which were $0.1 million for the three months ended October 4, 2026, and primarily consisted of a change in contingent consideration, as compared to $0.2 million for the three months ended September 28, 2025. Acquisition and divestiture-related expenses, which primarily consisted of legal and integration costs, were $0.1 million for the three months ended October 4, 2026, as compared to $0.3 million for the three months ended September 28, 2025. Significant litigation matters and settlements decreased, and were $0.2 million for the three months ended October 4, 2026, as compared to $0.8 million for the three months ended September 28, 2025. Transformation costs were $0.6 million for the three months ended October 4, 2026, as compared to $5.1 million for the three months ended September 28, 2025. Excluding the items noted above, selling, general and administrative expenses increased due to employee incentive compensation.

Previous wording

Selling, general and administrative expenses for the six months ended July 5, 2026 were $532.5 million, as compared to $498.2 million for the six months ended June 29, 2025, an increase of $34.2 million, or 7%. As a percentage of revenue, selling, general and administrative expenses increased and were 37.0% for the six months ended July 5, 2026, as compared to 36.0% for the six months ended June 29, 2025. Amortization of intangible assets increased and was $100.2 million for the six months ended July 5, 2026, as compared to $97.1 million for the six months ended June 29, 2025. Restructuring and other costs increased and were $46.2 million for the six months ended July 5, 2026, as compared to $14.4 million for the six months ended June 29, 2025. Restructuring and other costs in the first and second quarters of fiscal year 2026 primarily consisted of charges associated with workforce reductions and facility consolidations in an effort to streamline operations, other exit costs, abandonments or associated asset write-downs, costs of terminating certain lease agreements or contracts, as well as costs associated with relocating facilities. For the six months ended July 5, 2026, severance actions associated with facility consolidations and cost reduction measures affected approximately 5% of our workforce. Costs for significant environmental matters were a net credit of $1.2 million for the six months ended June 29, 2025. The above increases were also partially offset by a decrease in significant litigation matters and settlements, which was $0.1 million for the six months ended July 5, 2026, as compared to $11.7 million for the six months ended June 29, 2025. Disposition of businesses and assets, net were a net credit of $5.1 million for the six months ended July 5, 2026. Acquisition and divestiture-related expenses, which primarily consisted of legal and integration costs, decreased and were $0.4 million for the six months ended July 5, 2026, as compared to $3.8 million for the six months ended June 29, 2025. Transformation costs were $0.1 millionfor the six months ended July 5, 2026. Purchase accounting adjustments, which primarily consisted of a change in contingent consideration, remained flat at $1.6 million for both the six months ended July 5, 2026 and the six months ended June 29, 2025. Excluding the items noted above, selling, general and administrative expenses increased due to the extra fiscal week in the first quarter as compared to the same period in the prior year, digital investments, and employee incentive compensation.

Current wording

Selling, general and administrative expenses for the nine months ended October 4, 2026 were $807.8 million, as compared to $740.2 million for the nine months ended September 28, 2025, an increase of $67.6 million, or 9%. The analysis in the remainder of this paragraph includes the effect of foreign exchange rate fluctuations. As a percentage of revenue, selling, general and administrative expenses increased and were 37.2% for the nine months ended October 4, 2026, as compared to 35.5% for the nine months ended September 28, 2025. Amortization of intangible assets increased and was $150.3 million for the nine months ended October 4, 2026, as compared to $145.9 million for the nine months ended September 28, 2025. Restructuring and other costs increased and were $74.5 million for the nine months ended October 4, 2026, as compared to $24.4 million for the nine months ended September 28, 2025. Restructuring and other costs in the first three quarters of fiscal year 2026 primarily consisted of charges associated with workforce reductions and facility consolidations in an effort to streamline operations, other exit costs, abandonments or associated asset write-downs, costs of terminating certain lease agreements or contracts, as well as costs associated with relocating facilities. For the nine months ended October 4, 2026, severance actions associated with facility consolidations and cost reduction measures affected approximately 7% of our workforce. Costs for significant environmental matters were a net credit of $1.2 million for the nine months ended September 28, 2025. The above increases were also partially offset by a decrease in significant litigation matters and settlements, which was $0.3 million for the nine months ended October 4, 2026, as compared to $12.5 million for the nine months ended September 28, 2025. Disposition of businesses and assets, net were a net credit of $5.1 million for the nine months ended October 4, 2026. Acquisition and divestiture-related expenses, which primarily consisted of legal and integration costs, decreased and were $0.5 million for the nine months ended October 4, 2026, as compared to $3.0 million for the nine months ended September 28, 2025. Transformation costs were $0.7 million for the nine months ended October 4, 2026, as compared to $6.2 million for the nine months ended September 28, 2025. Purchase accounting adjustments, which primarily consisted of a change in contingent consideration, was down slightly at $1.7 million for the nine months ended October 4, 2026, as compared to $1.8 million for the nine months ended September 28, 2025. Excluding the items noted above, selling, general and administrative expenses increased due to the extra fiscal week in the first quarter as compared to the same period in the prior year, digital investments, and employee incentive compensation.

Previous wording

Research and development expenses for the three months ended July 5, 2026 were $49.0 million, as compared to $53.3 million for the three months ended June 29, 2025, a decrease of $4.3 million, or 8%. As a percentage of revenue, research and development expenses decreased and were 6.7% for the three months ended July 5, 2026, as compared to 7.4% for the three months ended June 29, 2025. The decrease in research and development expenses was primarily driven by cost containment initiatives.

Current wording

Research and development expenses for the three months ended October 4, 2026 were $48.1 million, as compared to $50.8 million for the three months ended September 28, 2025, a decrease of $2.7 million, or 5%. The analysis in the remainder of this paragraph includes the effect of foreign exchange rate fluctuations. As a percentage of revenue, research and development expenses decreased and were 6.6% for the three months ended October 4, 2026, as compared to 7.3% for the three months ended September 28, 2025. The decrease in research and development expenses was primarily driven by cost containment initiatives.

Previous wording

Research and development expenses for both the six months ended July 5, 2026 and the six months ended June 29, 2025 were flat at $106.9 million. As a percentage of revenue, research and development expenses decreased and were 7.4% for the six months ended July 5, 2026, as compared to 7.7% for the six months ended June 29, 2025. The change in research and development expenses was primarily driven by cost containment initiatives offsetting increased costs due to the extra fiscal week in the six months ended July 5, 2026 .

Current wording

Research and development expenses for the nine months ended October 4, 2026 were $155.0 million, as compared to $157.7 million for the nine months ended September 28, 2025, a decrease of $2.7 million, or 2%. The analysis in the remainder of this paragraph includes the effect of foreign exchange rate fluctuations. As a percentage of revenue, research and development expenses decreased and were 7.1% for the nine months ended October 4, 2026, as compared to 7.6% for the nine months ended September 28, 2025. The decrease in research and development expenses was primarily driven by cost containment initiatives, partially offset by increased costs due to the extra fiscal week in the nine months ended October 4, 2026.

Previous wording

The decrease in interest income for the three months ended July 5, 2026 as compared to the three months ended June 29, 2025 was primarily due to decreases in interest rates and lower cash balances. Interest expense for the three months ended July 5, 2026 remained flat as compared to the same period in the prior year.

Current wording

The decrease in interest income for the three months ended October 4, 2026 as compared to the three months ended September 28, 2025 was primarily due to lower cash balances. The decrease in interest expense for the three months ended October 4, 2026 as compared to the three months ended September 28, 2025 was primarily due to the repayment of the 2026 Notes in July 2026.

Previous wording

The decrease in interest income for the six months ended July 5, 2026 as compared to the six months ended June 29, 2025 was primarily due to decreases in interest rates and lower cash balances. Interest expense was higher for the six months ended July 5, 2026 as compared to the same period in the prior year primarily due to the extra fiscal week in the first quarter as compared to the same period in the prior year, which resulted in one additional week of accrued interest as compared to the six months ended June 29, 2025.

Current wording

The decrease in interest income for the nine months ended October 4, 2026 as compared to the nine months ended September 28, 2025 was primarily due to lower cash balances. Interest expense was lower for the nine months ended October 4, 2026 as compared to the same period in the prior year primarily due to the repayment of the 2026 Notes in July 2026, partially offset by higher interest expense due to the extra fiscal week in the first quarter of 2026 as compared to the same period in the prior year.

Previous wording

The provision for income taxes from continuing operations was $10.1 million for the three months ended July 5, 2026, as compared to $13.4 million for the three months ended June 29, 2025. The provision for income taxes from continuing operations was $19.1 million for the six months ended July 5, 2026, as compared to $24.1 million for the six months ended June 29, 2025.

Current wording

The provision for income taxes from continuing operations was $15.1 million for the three months ended October 4, 2026, as compared to $8.5 million for the three months ended September 28, 2025. The provision for income taxes from continuing operations was $34.2 million for the nine months ended October 4, 2026, as compared to $32.6 million for the nine months ended September 28, 2025.

Previous wording

The effective tax rate from continuing operations was 15.8% and 16.9% for the three and six months ended July 5, 2026, as compared to 19.6% and 19.9% for the three and six months ended June 29, 2025. The effective tax rate for the three and six months ended July 5, 2026 was lower as compared to the three and six months ended June 29, 2025 primarily due to favorable impacts related to state deferred tax remeasurements in fiscal year 2026 of $2.4 million. We expect that the effective tax rate on continuing operations, before discrete items, will be approximately 20% during fiscal year 2026.

Current wording

The effective tax rate from continuing operations was 19.4% and 17.9% for the three and nine months ended October 4, 2026, as compared to 15.2% and 18.5% for the three and nine months ended September 28, 2025. The effective tax rate for the three months ended October 4, 2026 was higher as compared to the three months ended September 28, 2025 primarily due to a shift in the geographical mix of earnings toward jurisdictions with higher statutory tax rates. The effective tax rate for the nine months ended October 4, 2026 was lower as compared to the nine months ended September 28, 2025 primarily driven by a discrete tax benefit of $4.3 million related to U.S. state taxes recognized in fiscal year 2026. We expect that the effective tax rate on continuing operations, before discrete items, will be approximately 20% during fiscal year 2026.

Previous wording

Revenue for the three months ended July 5, 2026 was $358.7 million, as compared to $365.9 million for the three months ended June 29, 2025, a decrease of $7.2 million, or 2%. The decrease in our Life Sciences segment revenue during the three months ended July 5, 2026 was driven by a decrease of $10.2 million in Software revenue, partially offset by an increase of $3.0 million in Life Sciences Solutions revenue.

Current wording

Revenue for the three months ended October 4, 2026 was $379.6 million, as compared to $342.8 million for the three months ended September 28, 2025, an increase of $36.8 million, or 11%. The increase in our Life Sciences segment revenue during the three months ended October 4, 2026 was driven by an increase of $21.6 million in Life Sciences Solutions revenue and an increase of $15.2 million in Software revenue.

Previous wording

Revenue for the six months ended July 5, 2026 was $720.5 million, as compared to $706.3 million for the six months ended June 29, 2025, an increase of $14.3 million, or 2%. The increase in our Life Sciences segment revenue during the six months ended July 5, 2026 was driven by an increase of $16.5 million in Life Sciences Solutions revenue, partially offset by a decrease of $2.3 million in Software revenue. Our Life Sciences segment benefited from an extra fiscal week for the six months ended July 5, 2026.

Current wording

Revenue for the nine months ended October 4, 2026 was $1,100.1 million, as compared to $1,049.1 million for the nine months ended September 28, 2025, an increase of $51.0 million, or 5%. The increase in our Life Sciences segment revenue during the nine months ended October 4, 2026 was driven by an increase of $38.1 million in Life Sciences Solutions revenue and an increase of $12.9 million in Software revenue. Our Life Sciences segment benefited from an extra fiscal week for the nine months ended October 4, 2026.

Previous wording

Segment operating income for the six months ended July 5, 2026 was $215.5 million, as compared to $221.2 million for the six months ended June 29, 2025, a decrease of $5.7 million, or 3%. Segment operating margin decreased 150 basis points in the six months ended July 5, 2026, as compared to the six months ended June 29, 2025, primarily due to strategic investments in software and new product development and impact of the extra fiscal week in the six months ended July 5, 2026.

Current wording

Segment operating income for the nine months ended October 4, 2026 was $335.0 million, as compared to $322.2 million for the nine months ended September 28, 2025, an increase of $12.8 million, or 4%. Segment operating margin decreased 30 basis points in the nine months ended October 4, 2026, as compared to the nine months ended September 28, 2025, primarily due to strategic investments in software and new product development and impact of the extra fiscal week in the nine months ended October 4, 2026.

Previous wording

Revenue for the three months ended July 5, 2026 was $371.0 million, as compared to $354.4 million for the three months ended June 29, 2025, an increase of $16.6 million, or 5%. Theincrease in our Diagnostics segment revenue duringthe three months ended July 5, 2026 was driven by an increase of $20.7 million in Reproductive Health revenue, partially offset by a decrease of $4.1 million in Immunodiagnostics revenue.

Current wording

Revenue for the three months ended October 4, 2026 was $349.3 million, as compared to $356.1 million for the three months ended September 28, 2025, a decrease of $6.8 million, or 2%. Thedecrease in our Diagnostics segment revenue duringthe three months ended October 4, 2026 was driven by a decrease of $10.5 million in Immunodiagnostics revenue, partially offset by an increase of $3.7 million in Reproductive Health revenue.

Previous wording

Revenue for the six months ended July 5, 2026 was $720.3 million, as compared to $678.8 million for the six months ended June 29, 2025, an increase of $41.5 million, or 6%. Theincrease in our Diagnostics segment revenue duringthe six months ended July 5, 2026 was driven by an increase of $41.3 million in Reproductive Health revenue and an increase of $0.2 million in Immunodiagnostics revenue. Our Diagnostics segment benefited from an extra fiscal week in the six months ended July 5, 2026.

Current wording

Revenue for the nine months ended October 4, 2026 was $1,069.6 million, as compared to $1,034.9 million for the nine months ended September 28, 2025, an increase of $34.7 million, or 3%. Theincrease in our Diagnostics segment revenue duringthe nine months ended October 4, 2026 was driven by an increase of $45.0 million in Reproductive Health revenue, partially offset by a decrease of $10.3 million in Immunodiagnostics revenue. Our Diagnostics segment benefited from an extra fiscal week in the nine months ended October 4, 2026.

Previous wording

Segment operating incomefor the three months ended July 5, 2026 was $112.9 million, as compared to $89.4 millionfor the three months ended June 29, 2025, an increase of $23.4 million, or 26%. Segment operating margin increased 520 basis points in the three months ended July 5, 2026, as compared to the three months ended June 29, 2025, primarily due to tariff refunds and cost containment initiatives.

Current wording

Segment operating incomefor the three months ended October 4, 2026 was $104.3 million, as compared to $89.4 millionfor the three months ended September 28, 2025, an increase of $14.9 million, or 17%. Segment operating margin increased 480 basis points in the three months ended October 4, 2026, as compared to the three months ended September 28, 2025, primarily due to restructuring benefit and cost containment initiatives.

Previous wording

Segment operating incomefor the six months ended July 5, 2026 was $189.0 million, as compared to $163.4 millionfor the six months ended June 29, 2025, an increase of $25.6 million, or 16%. Segment operating margin increased 220 basis points in the six months ended July 5, 2026, as compared to the six months ended June 29, 2025, primarily due to tariff refunds and cost containment initiatives, partially offset by product mix shift and the impact of the extra fiscal week in the six months ended July 5, 2026.

Current wording

Segment operating incomefor the nine months ended October 4, 2026 was $293.3 million, as compared to $252.8 millionfor the nine months ended September 28, 2025, an increase of $40.5 million, or 16%. Segment operating margin increased 300 basis points in the nine months ended October 4, 2026, as compared to the nine months ended September 28, 2025, primarily due to tariff refunds, restructuring benefit, and cost containment initiatives, partially offset by product mix shift and the impact of the extra fiscal week in the nine months ended October 4, 2026.

Previous wording

At July 5, 2026, we had cash and cash equivalents of$1,022.9 million, of which $544.5 million was held by our non-U.S. subsidiaries, and we had$1.5 billion of borrowing capacity available under our senior unsecured revolving credit facility. We use a variety of cash redeployment and financing strategies to ensure that our worldwide cash is available in the locations in which it is needed.

Current wording

At October 4, 2026, we had cash and cash equivalents of$592.8 million, of which $504.0 million was held by our non-U.S. subsidiaries, and we had$1.5 billion of borrowing capacity available under our senior unsecured revolving credit facility. We use a variety of cash redeployment and financing strategies to ensure that our worldwide cash is available in the locations in which it is needed.

Previous wording

On October 23, 2025, our Board of Directors (our “Board”) authorized us to repurchase shares of common stock for anaggregate amount up to $1.0 billion under a stock repurchase program (the “Repurchase Program”). The Repurchase Program will expire on October 22, 2027 unless terminated earlier by our Board and may be suspended or discontinued at anytime. During the three months ended July 5, 2026, we repurchased 93,303 shares of common stock under the Repurchase Program for an aggregate cost of $7.8 million. As of July 5, 2026,$792.7 million remained available for aggregate repurchases ofshares under the Repurchase Program. There have been no share repurchases subsequent to the second quarter of fiscal year 2026. If we continue to repurchase shares, the Repurchase Program will be funded using our existing financial resources, including cash and cash equivalents, and our existing senior unsecured revolving credit facility.

Current wording

On October 23, 2025, our Board of Directors (our “Board”) authorized us to repurchase shares of common stock for anaggregate amount up to $1.0 billion under a stock repurchase program (the “Repurchase Program”). The Repurchase Program will expire on October 22, 2027 unless terminated earlier by our Board and may be suspended or discontinued at anytime. During the three months ended October 4, 2026, we did not repurchase any shares of common stock under the Repurchase Program. As of October 4, 2026,$792.7 million remained available for aggregate repurchases ofshares under the Repurchase Program. There have been no share repurchases under the Repurchase Program subsequent to the third quarter of fiscal year

Previous wording

As of July 5, 2026, we may have to pay contingent consideration related to acquisi tions with open contingency periods of up to $71.2 million. As of July 5, 2026, we have recorded contingent consideration obligations of $15.4 million, of which $4.0 million was recorded in accrued expenses and other current liabilities, and $11.4 million was recorded in long-term liabilities. The maximum earnout period for acquisitions with open contingency periods is 5.4 years from July 5, 2026, and the remaining weighted average expected earnout period at July 5, 2026 was 3.0 years.

Current wording

As of October 4, 2026, we may have to pay contingent consideration related to acquisi tions with open contingency periods of up to $70.5 million. As of October 4, 2026, we have recorded contingent consideration obligations of $15.4 million, of which $5.2 million was recorded in accrued expenses and other current liabilities, and $10.2 million was recorded in long-term liabilities. The maximum earnout period for acquisitions with open contingency periods is 5.2 years from October 4, 2026, and the remaining weighted average expected earnout period at October 4, 2026 was 2.8 years.

Previous wording

Operating Activities. Net cash provided by operating activities of ourcontinuing operations was $317.8 million for the six months ended July 5, 2026, as compared to $268.4 million for the six months ended June 29, 2025, an increase of $49.4 million. The cash provided by operating activities for the six months ended July 5, 2026 was principally a result of adjustments for non-cash charges aggregating to $281.3 million, including depreciation and amortization of $207.1 million and income from continuing operations of $94.4 million, partially offset by a net cash decrease in working capital of $57.8 million, primarily due to annual employee incentive compensation payout and timing of inventory build and vendor payments, partially offset by robust collections performance. The cash provided by operating activities for the six months ended June 29, 2025 was principally a result of adjustments for non-cash charges aggregating to $233.7 million, including depreciation and amortization of $200.2 million, and income from continuing operations of $96.9 million, partially offset by a net cash decrease in working capital of $62.2 million.

Current wording

Operating Activities. Net cash provided by operating activities of ourcontinuing operations was $484.5 million for the nine months ended October 4, 2026, as compared to $407.0 million for the nine months ended September 28, 2025, an increase of $77.5 million. The cash provided by operating activities for the nine months ended October 4, 2026 was principally a result of adjustments for non-cash charges aggregating to $421.7 million, including depreciation and amortization of $310.0 million and income from continuing operations of $157.0 million, partially offset by a net cash decrease in working capital of $94.2 million, primarily due to timing of payments and inventory build, partially offset by robust collections performance. The cash provided by operating activities for the nine months ended September 28, 2025 was principally a result of adjustments for non-cash charges aggregating to $360.8 million, including depreciation and amortization of $302.3 million, and income from continuing operations of $144.1 million, partially offset by a net cash decrease in working capital of $97.9 million.

Previous wording

Investing Activities. Net cash used in investing activitiesof our continuing operationswas $81.8 million for the six months ended July 5, 2026, as compared to $34.6 million for the six months ended June 29, 2025, an increase of $47.2 million primarily due to cash paid for acquisitions, net of cash acquired of $67.1 million during the six months ended July 5, 2026. During the six months ended July 5, 2026, net cash used for capital expenditures was $30.8 million, as compared to $34.9 million for the six months ended June 29, 2025. During the six months ended July 5, 2026, purchases of investments and notes receivables were $3.6 million. The cash used in investing activities during the six months ended July 5, 2026 was partially offset by $12.0 million of proceeds from disposition of property, plant and equipment. During the six months ended July 5, 2026, proceeds from investments and notes receivable amounted to $7.5 million. During the six months ended July 5, 2026, proceeds from disposition of businesses and assets amounted to $0.2 million, remaining flat compared to the six months ended June 29, 2025.

Current wording

$44.2 million primarily due to cash paid for acquisitions, net of cash acquired of $67.1 million during the nine months ended October 4, 2026. During the nine months ended October 4, 2026, net cash used for capital expenditures was $45.2 million, as compared to $53.4 million for the nine months ended September 28, 2025. During the nine months ended October 4, 2026, purchases of investments and notes receivables were $4.8 million. The cash used in investing activities during the nine months ended October 4, 2026 was partially offset by $12.0 million of proceeds from disposition of property, plant and equipment. During the nine months ended October 4, 2026, proceeds from investments and notes receivable amounted to $7.5 million. During the nine months ended October 4, 2026, proceeds from disposition of businesses and assets amounted to $0.2 million, remaining flat compared to the nine months ended September 28, 2025.

Previous wording

Financing Activities. Net cash used in financing activities was $112.1 million for the six months ended July 5, 2026, as compared to $466.1 million for the six months ended June 29, 2025, a decrease of $354.1 million. During the six months ended July 5, 2026, we repurchased shares of our common stock for a total cost of $102.5 million, as compared to $447.5 million in the prior year period. We paid $15.7 million in dividends for the six months ended July 5, 2026, as compared to $16.7 million for the six months ended June 29, 2025. We paid $0.4 million for acquisition-related contingent consideration during the six months ended July 5, 2026, as compared to $2.0 million for the six months ended June 29, 2025. During the six months ended June 29, 2025, we made net payments of$2.6 millionon debts. The cash used in financing activities during the six months ended July 5, 2026 was partially offset by proceeds from the issuance of common stock under our stock plans of $6.4 million during the six months ended July 5, 2026, as compared to $2.6 million for the six months ended June 29, 2025.

Current wording

Financing Activities. Net cash used in financing activities was $687.7 million for the nine months ended October 4, 2026, as compared to $681.2 million for the nine months ended September 28, 2025, an increase of $6.5 million. During the nine months ended October 4, 2026, we made net payments of$571.2 millionon debts, as compared to$2.6 million during the nine months ended September 28, 2025. During the nine months ended October 4, 2026, we repurchased shares of our common stock for a total cost of $102.6 million, as compared to $652.5 million in the prior year period. We paid $23.5 million in dividends for the nine months ended October 4, 2026, as compared to $24.8 million for the nine months ended September 28, 2025. We paid $0.4 million for acquisition-related contingent consideration during the nine months ended October 4, 2026, as compared to $3.8 million for the nine months ended September 28, 2025. The cash used in financing activities during the nine months ended October 4, 2026 was partially offset by proceeds from the issuance of common stock under our stock plans of $9.9 million during the nine months ended October 4, 2026, as compared to $2.6 million for the nine months ended September 28, 2025.

Previous wording

Subsequent to the second quarter of fiscal year 2026, we repaid upon maturity all of our outstanding €500,000 Principal 1.875% Senior Unsecured Notes due in 2026 (the “2026 Notes”) at an aggregate principal amount of €500.0 million ($571.2 million). See Note 7, Debt, in the Notes to Condensed Consolidated Financial Statements and Note 13, Debt, to our audited consolidated financial statements in the 2025 Form 10-K for a detailed discussion of our borrowing arrangements.

Current wording

During the third quarter of fiscal year 2026, we repaid upon maturity all of our outstanding €500,000 Principal 1.875% Senior Unsecured Notes that were due in 2026 at an aggregate principal amount of €500.0 million ($571.2 million). During the third quarter of fiscal year 2026, we borrowed $25.0 million under our senior unsecured revolving credit facility and subsequently repaid the full amount during the quarter. See Note 7, Debt, in the Notes to Condensed Consolidated Financial Statements and Note 13, Debt, to our audited consolidated financial statements in the 2025 Form 10-K for a detailed discussion of our borrowing arrangements.

Previous wording

Our Board declared a regular quarterly cash dividend of $0.07 per share for each of the first two quartersof fiscal year 2026 and in each quarter of fiscal year 2025. At July 5, 2026, we had accrued $7.8 million for dividends declared on April 30, 2026 for the second quarter of fiscal year 2026 that were paid in August 2026. On July 31, 2026, we announced that our Board had declared a quarterly dividend of $0.07 per share for the third quarter of fiscal year 2026 that will be payable in November 2026. In the future, our Board may determine to reduce or eliminate our common stock dividend in order to fund investments for growth, repurchase shares or conserve capital resources.

Current wording

Our Board declared a regular quarterly cash dividend of $0.07 per share for each of the first two quartersof fiscal year 2026 and in each quarter of fiscal year 2025. At October 4, 2026, we had accrued $7.8 million for dividends declared on July 31, 2026 for the third quarter of fiscal year 2026 that will be payable in November 2026. On October 30, 2026, we announced that our Board had declared a quarterly dividend of $0.07 per share for the fourth quarter of fiscal year 2026 that will be payable in February 2027. In the future, our Board may determine to reduce or eliminate our common stock dividend in order to fund investments for growth, repurchase shares or conserve capital resources.

Previous wording

See Note 1, Nature of Operations and Accounting Policies, to our audited consolidated financial statements in the 2025 Form 10-K for a summary of recently adopted new accounting pronouncements during the fiscal year ended December 28, 2025. We have not adopted any new accounting pronouncements during the six months ended July 5, 2026.

Current wording

See Note 1, Nature of Operations and Accounting Policies, to our audited consolidated financial statements in the 2025 Form 10-K for a summary of recently adopted new accounting pronouncements during the fiscal year ended December 28, 2025. We have not adopted any new accounting pronouncements during thenine months ended October 4, 2026.